Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, shares insights into a first-in-human Phase I trial investigating the safety and efficacy of combining a gamma secretase inhibitor (GSI) with BCMA CAR-T cells in patients with relapsed/refractory (R/R) multiple myeloma. GSIs are agents which increase BCMA density on plasma cells, and results suggest that combining these two agents may provide a benefit to patients, although further research is required. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar